Hadasit, the innovation engine of Hadassah Medical Center in Jerusalem, is the doorway to Hadassah technologies and research excellence. We transform cutting-edge research into marketable medical technologies, improving human health, and changing the world for the better. Hadasit works alongside Hadassah researchers in the fields of pharmaceuticals, molecular diagnostics, medical device, life science, biotech, and digital health. Our role: 📌 Hadasit identifies, protects, nurtures and commercializes the diverse innovations made at Hadassah Medical Center. 📌 Hadasit invests in start-up companies, licenses technologies, and collaborates with leading international companies, institutions and research facilities. 📌 Provide companies with R&D services and preclinical studies performed with the scientific and technological excellence at Hadassah Medical center laboratories To date, Hadasit has helped establish over 70 companies, including Hadasit Bio-Holdings (TASE: HDST), Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), Immuron (ASX: IMC), Insuline Medical (INSL.TA), CardioVia, SynCath NeuroScience, eDAS Healthcare, Cell Cure Neurosciences, Exalenz Bioscience, Enlivex Pharmaceuticals, KAHR Medical, Brainstorm (NASDAQ: BCLI), Akashi Therapeutics, PamBio, Fidmi Medical, GuideIn Medical, Cordio Medical, Granalix, Swift-Duct, Nobio, BrainWatch Tech and more. Specific fields of expertise include Oncology, Immunotherapy, Cell therapy, Drug discovery, Drug development, Personalized medicine, Artificial Intelligence in the Pharmaceutical industry, Molecular diagnostics, Ophthalmology, Cardiology, Microbiology, Virology, Pulmonology and Dentistry. Hadasit's major driver is making a robust impact on healthcare by building optimum partnerships between academy and industry.